Cytomx Therapeutics, INC Form 4 insider transactions

Yu-Waye Chu, Chief Medical Officer of CytomX Therapeutics, sold 4,025 shares of common stock to cover tax obligations related to vesting restricted stock units.

Lloyd A. Rowland, General Counsel of CytomX Therapeutics, sold 10,203 shares of common stock to satisfy tax obligations related to vesting restricted stock units.

Marcia Belvin, SVP, Chief Scientific Officer of CytomX Therapeutics, sold 19,512 shares of common stock on March 18, 2025, to cover tax obligations related to vesting restricted stock units.

Marcia Belvin, SVP and Chief Scientific Officer of CytomX Therapeutics, files an amended Form 4/A to correct errors in the previously reported number of securities acquired and beneficially owned.

Marcia Belvin, SVP, Chief Scientific Officer of CytomX Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) on February 4, 2025.

Yu-Waye Chu, Chief Medical Officer of CytomX Therapeutics, reports the acquisition of restricted stock units and stock options in the company.

Christopher Ogden, CFO of CytomX Therapeutics, reports the acquisition of restricted stock units and stock options.

CytomX Therapeutics CEO Sean McCarthy reports the acquisition of common stock and stock options, as well as adjustments to his holdings of restricted stock units.

Jeffrey Landau, Chief Business Officer of CytomX Therapeutics, reports the vesting of performance stock units and subsequent sale of shares to cover tax obligations.

Marcia Belvin, SVP and Chief Scientific Officer of CytomX Therapeutics, reports the vesting of performance stock units and subsequent sale of shares to cover tax obligations.

Lloyd Rowland, General Counsel of CytomX Therapeutics, reports the vesting of performance stock units and subsequent sale of shares to cover tax obligations.

Christopher Ogden, CFO of CytomX Therapeutics, reports the vesting of performance stock units and subsequent sale of shares to cover tax obligations.

CytomX Therapeutics CEO Sean McCarthy reports the vesting of performance stock units and subsequent sale of shares to cover tax obligations.

Christopher Ogden, CFO of CytomX Therapeutics, reports the acquisition of restricted stock units and stock options.

Director Matthew P. Young acquired 38,000 stock options in CytomX Therapeutics, Inc. on May 15, 2024.

Director Zhen Su acquired 38,000 stock options in CytomX Therapeutics on May 15, 2024, according to a Form 4 filing with the SEC.

Director Mani Mohindru of CytomX Therapeutics acquired stock options exercisable for 38,000 shares of common stock on May 15, 2024.

Director James R. Meyers of CytomX Therapeutics acquired 38,000 stock options on May 15, 2024, exercisable at $1.96 per share.

Director Elaine V. Jones reports the acquisition of stock options in CytomX Therapeutics.

Director Halley E. Gilbert acquired 38,000 stock options in CytomX Therapeutics on May 15, 2024, according to a Form 4 filing.

Alan Ashworth, a director of CytomX Therapeutics, acquired stock options for 38,000 shares on May 15, 2024.

CytomX Therapeutics CEO Sean A. McCarthy exercised stock options and acquired shares of common stock on March 26, 2024.

Director Zhen Su acquired 76,000 stock options in CytomX Therapeutics on March 20, 2024, according to a Form 4 filing.

Lloyd Rowland, General Counsel of CytomX Therapeutics, sold 5,268 shares of common stock on March 19, 2024, to cover tax obligations related to vesting restricted stock units.

CytomX Therapeutics CEO Sean A. McCarthy sold 20,223 shares of common stock on March 19, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.

Christopher Ogden, SVP of Finance and Accounting at CytomX Therapeutics, sold 2,971 shares of common stock on March 19, 2024, to satisfy tax obligations related to vesting restricted stock units.

Marcia Belvin, SVP, Chief Scientific Officer of CytomX Therapeutics, sold 12,795 shares of common stock on March 19, 2024, to cover tax obligations related to vesting restricted stock units.

Jeffrey B Landau, Chief Business Officer of CytomX Therapeutics, sold shares of common stock to cover tax obligations related to vesting restricted stock units.